AKBA is an active triterpenoid compound from the extract of Boswellia serrata and Boswellia carteri Birdw, exerts anti-inflammatory therapeutic effects and noncompetitively inhibits 5-lipoxygenase, topoisomerase, and leukocyte elastase. AKBA reduced the impact of proliferative retinopathies, protecting neurons against ischemic injury involving the Nrf2/HO-1 pathway. AKBA significantly inhibited human colon adenocarcinoma growth, showing arrest of the cell cycle in G1-phase and induction of apoptosis.
In vivo, AKBA significantly prevented the formation of intestinal adenomatous polyps without toxicity to mice. AKBA administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO 10 mM|
Quantification of AKBA in Boswellia sacra Using NIRS Coupled with PLSR as an Alternative Method and Cross-Validation by HPLC.
Rehman NU, et al. Phytochem Anal. 2018 Mar;29(2):137-143. PMID: 28881407.
Adsorption kinetics, isotherm, and thermodynamics studies of acetyl-11-keto-β-boswellic acids (AKBA) from Boswellia serrata extract using macroporous resin.
Niphadkar SS, et al. Prep Biochem Biotechnol. 2017 Sep 14;47(8):804-812. PMID: 28662360.
Synthesis of new analogs of AKBA and evaluation of their anti-inflammatory activities.
Meka B, et al. Bioorg Med Chem. 2017 Feb 15;25(4):1374-1388. PMID: 28110820.
Quantitative Determination of 3-O-Acetyl-11-Keto-βBoswellic Acid (AKBA) and Other Boswellic Acids in Boswellia sacra Flueck (syn. B. carteri Birdw) and Boswellia serrata Roxb.
Mannino G, et al. Molecules. 2016 Oct 6;21(10). PMID: 27782055.
|Related Lipoxygenase Products|
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and prostaglandin synthetase (cyclooxygenase, COX) with IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and seminal vesicle prostaglandin synthetase, respectively.
BHQ is a inhibitor of SERCA ATPase.
MK 886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) (IC50 = 44 nM).
GSK2190915 (AM803), a potent FLAP inhibitor, prevents the synthesis of leukotrienes and 5-oxo-ETE, with IC50 of 76 nM for inhibition of LTB4 in human blood, provides treatment for asthma.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.